Scinai Immunotherapeutics Announces $4 Million Financing Deal
Scinai Immunotherapeutics (SCNI) has entered into agreements with an existing institutional investor to raise approximately $4 million in gross proceeds through a private placement. The deal involves the issuance of 2.46 million ADSs or pre-funded warrants, along with Series A-1 warrants that allow for the purchase of up to 3.69 million additional ADSs. Following the announcement, SCNI's shares experienced a decline in value on NASDAQ, indicating investor concern over potential dilution and financial pressures facing the company. The financing is intended to support Scinai’s ongoing operations but has raised questions about its long-term capital needs.
